Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech Backers Learn To Live With Exit-By-Earn-Out

This article was originally published in The Pink Sheet Daily

Executive Summary

Even as both public investors and pharma companies more vigorously sniff out biopharma opportunities, exits for venture-backed firms remain scarce. Can risk-sharing acquisitions save the day?
Advertisement

Related Content

Clovis Oncology Seeks $149.5 Million IPO
Clovis Oncology Seeks $149.5 Million IPO
Emergent BioSolutions Takes Out Troubled Trubion For $97 Million
Biopharma Quarterly Statistics Q1 2010
Second Time Around: Cephalon Buys Ception Based On Cinquil Data In Asthma
2009's Private Biotech Acquisitions Are a Tale of Two Step-Ups
Novartis Offers $120 Million For Corthera Eyeing Phase III Acute Cardiology Product
Novartis Offers $120 Million For Corthera Eyeing Phase III Acute Cardiology Product
For a Look at IPO Future, Follow the Follow-On?
Private Biotech M&A Review: Has the Market Lost Steam?

Topics

Advertisement
UsernamePublicRestriction

Register

PS070587

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel